4results about How to "Reduce myocardial damage" patented technology

This invention belongs to the field of medical technology, specifically relating to the application of mitochondrial transplantation to regulate the immune-metabolic network in the treatment of myocardial dysfunction after cardiac arrest. The mitochondrial transplantation is performed within 0.5-2 hours after the restoration of spontaneous cardiac circulation. This technical solution, through multi-omics integrated analysis, proposes that mitochondrial transplantation exerts a cardioprotective effect by regulating the immune-metabolic-mitochondrial triaxial synergistic network, providing a new research direction for the precision treatment of myocardial dysfunction after cardiac arrest.

The invention belongs to the technical field of medicines, and provides application of fritillaria alkaloid in preparation of a medicine for treating cardiomyopathy induced by chemotherapeutic drugs. The fritillaria alkaloid is fritillaria pallidiflora alkaloid; the chemotherapeutic drug is an anthracycline chemotherapeutic drug; the anthracycline chemotherapeutic drug is adriamycin. The fritillaria pallidiflora alkaloid can prevent and / or treat doxorubicin-induced cardiomyopathy by resisting myocardial fibrosis and relieving myocardial damage. The fritillaria pallidiflora alkaloid is a natural fritillaria pallidiflora alkaloid, through a multi-target action mechanism, cardiac function decline and cardiomyopathy damage caused by adriamycin are effectively relieved, and a novel candidate drug with potential and a treatment strategy are provided for preventing or treating chemotherapy drug induced cardiomyopathy.

The invention relates to the technical field of pharmaceutical preparations, in particular to a traditional Chinese medicine compound and preparation for treating coronary heart disease and a preparation method and application of the traditional Chinese medicine compound and preparation. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 10-30 parts of astragalus membranaceus, 5-15 parts of rhodiola rosea, 10-30 parts of salvia miltiorrhiza, 5-15 parts of ligusticum wallichii, 10-30 parts of trichosanthes kirilowii maxim, 5-15 parts of allium macrostemon, 5-15 parts of folium ginkgo, 10-30 parts of radix puerariae, 10-30 parts of radix ophiopogonis, 3-10 parts of schisandra chinensis, 15-30 parts of oyster, 5-15 parts of cassia twig and 3-10 parts of liquorice. Animal experiment results show that the traditional Chinese medicine composition provided by the invention has remarkable and multi-aspect curative effect advantages in the aspect of treating a coronary heart disease rat model. The traditional Chinese medicine composition not only can enhance myocardial contractility and recover heart blood pumping function, but also can inhibit inflammatory response, relieve myocardial damage, effectively relieve myocardial structure damage and protect myocardial tissue integrity. In addition, a proportional experiment result shows that the effect of the composition provided by the invention can be obviously weakened by losing any medicine pair, so that all the medicines in the formula cannot be absent.

The application relates to the field of biological medicine, and provides application of OpiCa1 mutant peptide DE-4A in antagonizing heart failure after myocardial infarction. Experiments prove that the polypeptide DE-4A can remodel myocardial calcium homeostasis by restoring RyR2 protein stability and blocking excessive activation of the CaMKII signal pathway. This mechanism effectively reduces myocardial injury and fibrosis, significantly improves ventricular remodeling and heart dysfunction after myocardial infarction, and provides new experimental evidence for the treatment of ischemic cardiomyopathy. DE-4A has the effects of improving myocardial contractile function, regulating Ca 2+ homeostasis, which may be a key link in the pharmacodynamic mechanism, and provides new experimental evidence for the treatment of ischemic heart disease.